Prof. Giovanni Bottegoni
Host Organization University of Urbino, Italy Dipartimento di Scienze Biomolecolari (DISB) Bottegoni Lab ALLODD Role Main Supervisor for ESR14 |
Brief Bio Giovanni Bottegoni began his scientific career with a master of science in pharmaceutical biotechnology. In 2006, he obtained his doctorate in medicinal chemistry from the Alma Mater Studiorum – University of Bologna, Faculty of Pharmacy. He spent two years as a research fellow the Scripps Research Institute in La Jolla, CA - USA and later joined the Istituto Italiano di Tecnologia (IIT), first as a postdoctoral fellow and eventually as a team leader at the Dept. of Drug Discovery and Development – Computation. After a few years in industry (BiKi Technologies, SoseiHeptares), he went back to an academic role, joining the School of Pharmacy at the University of Birmingham in 2018 and, eventually, the University of Urbino "Carlo Bo" (Urbino, Italy) as associate professor of medicinal chemistry. Since 2013, he has been integrating his scientific background and first-hand knowledge of the drug discovery process with managerial skills. In 2014, he obtained a Certificate of Advanced Studies in Management of Biotech, Medtech and Pharma Ventures issued by the École Polytechnique Fédérale de Lausanne (EPFL, CH). In 2015, he completed with honours a master program in International Health Care Management, Economics and Policy (MIHMEP) offered by Bocconi School of Management (Milan, IT). In 2014, together with four other scientists, he co-founded BiKi Technologies, an innovative start-up company that develops and commercialises advanced software solutions for computational medicinal chemistry and, for two years, he was CEO of the company. Prof. Bottegoni has extensive experience in coordinating preclinical drug discovery projects. He co-authored over 50 scientific studies published in international peer-reviewed journals and books and is co-inventor of four patents. Selected Publications Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration Di Fruscia P, Carbone A, Bottegoni G, Berti F, Giacomina F, Ponzano S, Pagliuca C, Fiasella A, Pizzirani D, Ortega JA, Nuzzi A, Tarozzo G, Mengatto L, Giampà R, Penna I, Russo D, Romeo E, Summa M, Bertorelli R, Armirotti A, Bertozzi SM, Reggiani A, Bandiera T, Bertozzi F J Med Chem. 2021, 64(18):13327-13355 https://doi.org/10.1021/acs.jmedchem.1c00575 Multi-target dopamine D3 receptor modulators: Actionable knowledge for drug design from molecular dynamics and machine learning Ferraro M, Decherchi S, De Simone A, Recanatini M, Cavalli A, Bottegoni G Eur J Med Chem. 2020, 188:111975 https://doi.org/10.1016/j.ejmech.2019.111975 Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727 Robertson N, Rappas M, Doré AS, Brown J, Bottegoni G, Koglin M, Cansfield J, Jazayeri A, Cooke RM, Marshall FH Nature. 2018, 553(7686):111-114 https://doi.org/10.1038/nature25025 Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase De Simone A, Russo D, Ruda GF, Micoli A, Ferraro M, Di Martino RM, Ottonello G, Summa M, Armirotti A, Bandiera T, Cavalli A, Bottegoni G J Med Chem. 2017, 60(6):2287-2304 https://doi.org/10.1021/acs.jmedchem.6b01578 Mapping Cholesterol Interaction Sites on Serotonin Transporter through Coarse-Grained Molecular Dynamics Ferraro M, Masetti M, Recanatini M, Cavalli A, Bottegoni G PLoS One. 2016, 11(12):e0166196 https://doi.org/10.1371/journal.pone.0166196 Synthesis, biological evaluation, and 3D QSAR study of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters as N-acylethanolamine acid amidase (NAAA) inhibitors Ponzano S, Berteotti A, Petracca R, Vitale R, Mengatto L, Bandiera T, Cavalli A, Piomelli D, Bertozzi F, Bottegoni G J Med Chem. 2014, 57(23):10101-10111 https://doi.org/10.1021/jm501455s Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase De Simone A, Ruda GF, Albani C, Tarozzo G, Bandiera T, Piomelli D, Cavalli A, Bottegoni G Chem Commun (Camb). 2014, 50(38):4904-4907 https://doi.org/10.1039/c4cc00967c |
|
|
This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956314.
|
|
